Literature DB >> 2362198

A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier.

K Fujimori1, D G Covell, J E Fletcher, J N Weinstein.   

Abstract

For successful use of radiolabeled monoclonal antibodies (MAbs) for diagnosis and therapy, it is helpful to understand both global and microscopic aspects of antibody biodistribution. In this study, antibody distribution in a tumor is simulated by splicing together information on global pharmacokinetics: transport across the capillary wall, diffusive penetration through the tumor interstitial space, and antigen-antibody interaction. The geometry simulated corresponds to spherical nodules of densely packed tumor cells. This modeling analysis demonstrates that: 1) antigen-antibody binding in tumors can retard antibody percolation; 2) high antibody affinity at a given dose tends to decrease antibody percolation because there are fewer free antibody molecules. The result is a more heterogeneous distribution; 3) the average antibody concentration in the tumor does not increase linearly with affinity; and 4) increasing antibody dose leads to better percolation and more uniform distribution. This mathematical model and the general principles developed here can be applied as well to other biologic ligands.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2362198

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  115 in total

1.  Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice.

Authors:  Daniela Bumbaca; Hong Xiang; C Andrew Boswell; Ruediger E Port; Shannon L Stainton; Eduardo E Mundo; Sheila Ulufatu; Anil Bagri; Frank-Peter Theil; Paul J Fielder; Leslie A Khawli; Ben-Quan Shen
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

2.  Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma.

Authors:  Steven I Park; Jaideep Shenoi; Shani M Frayo; Donald K Hamlin; Yukang Lin; D Scott Wilbur; Patrick S Stayton; Nural Orgun; Mark Hylarides; Franz Buchegger; Aimee L Kenoyer; Amanda Axtman; Ajay K Gopal; Damian J Green; John M Pagel; Oliver W Press
Journal:  Clin Cancer Res       Date:  2011-10-05       Impact factor: 12.531

Review 3.  Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier.

Authors:  Ankit I Mehta; Adam M Brufsky; John H Sampson
Journal:  Cancer Treat Rev       Date:  2012-06-22       Impact factor: 12.111

Review 4.  Therapeutic antibodies: successes, limitations and hopes for the future.

Authors:  Patrick Chames; Marc Van Regenmortel; Etienne Weiss; Daniel Baty
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

5.  Affinity maturation of an ERBB2-targeted SPECT imaging peptide by in vivo phage display.

Authors:  Benjamin M Larimer; William D Thomas; George P Smith; Susan L Deutscher
Journal:  Mol Imaging Biol       Date:  2014-08       Impact factor: 3.488

6.  Monitoring therapeutic monoclonal antibodies in brain tumor.

Authors:  Rima Ait-Belkacem; Caroline Berenguer; Claude Villard; L'Houcine Ouafik; Dominique Figarella-Branger; Alain Beck; Olivier Chinot; Daniel Lafitte
Journal:  MAbs       Date:  2014       Impact factor: 5.857

7.  Quantitative spatiotemporal analysis of antibody fragment diffusion and endocytic consumption in tumor spheroids.

Authors:  Greg M Thurber; K Dane Wittrup
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

8.  Semiquantitative assessment of the microdistribution of fluorescence-labeled monoclonal antibody in small peritoneal disseminations of ovarian cancer.

Authors:  Nobuyuki Kosaka; Mikako Ogawa; David S Paik; Chang H Paik; Peter L Choyke; Hisataka Kobayashi
Journal:  Cancer Sci       Date:  2009-10-31       Impact factor: 6.716

9.  Intracranial elimination of human glioblastoma brain tumors in nude rats using the bispecific ligand-directed toxin, DTEGF13 and convection enhanced delivery.

Authors:  Seunguk Oh; John R Ohlfest; Deborah A Todhunter; Vincent D Vallera; Walter A Hall; Hua Chen; Daniel A Vallera
Journal:  J Neurooncol       Date:  2009-06-11       Impact factor: 4.130

Review 10.  Challenges to effective cancer nanotheranostics.

Authors:  Marites P Melancon; R Jason Stafford; Chun Li
Journal:  J Control Release       Date:  2012-08-18       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.